Release Date: December 15, 2025
Expiration Date: December 15, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEAs) has transformed as novel targeted and immunologic therapies have been characterized. In particular, multiple treatment approaches are now available for management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast features a discussion of current
best practices for the management of HER2-positive advanced or metastatic GEAs,
led by Rohit Gosain, MD; and Rahul Gosain, MD, and featuring a faculty expert
focused on the management of these tumors.
Target Audience
This educational activity is directed toward US and Global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review guideline recommendations for biomarker testing in GEA
- Evaluate how HER2 positivity influences treatment decisions in GEA and discuss strategies to address gaps in HER2 testing and therapy access
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here